S
Sirnaomics
A biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology
About Sirnaomics
Sirnaomics Inc. is a biopharmaceutical company that focuses on the discovery and development of RNA interference (RNAi) therapeutics. RNAi is a biological process where RNA molecules inhibit gene expression, effectively silencing targeted genes. This technology is particularly promising for treating various diseases, including cancers and viral infections.
Read full description
The company primarily serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. Sirnaomics operates in the global biopharmaceutical market, which is characterized by rapid innovation and significant investment in research and development.
Sirnaomics' business model revolves around developing novel RNAi drug candidates and bringing them through clinical trials to market. They also engage in strategic partnerships to enhance their development capabilities. For instance, they have partnered with Precision NanoSystems to develop and manufacture new RNAi drug candidates using advanced technology platforms.
The company generates revenue through several channels. Primarily, they earn money by licensing their RNAi technologies and drug candidates to larger pharmaceutical companies. Additionally, they may receive milestone payments and royalties from these partnerships. Sirnaomics also benefits from grants and funding aimed at advancing medical research.
Recently, Sirnaomics announced the spin-off of RNAimmune, a subsidiary focused on developing mRNA therapeutics and vaccines. This move allows them to diversify their portfolio and tap into the growing market for mRNA-based treatments, which gained significant attention during the COVID-19 pandemic.
In summary, Sirnaomics is a key player in the biopharmaceutical industry, leveraging RNAi technology to develop innovative treatments for serious diseases. Their strategic partnerships and diversified approach position them well for future growth.
At a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Germantown, United States
- Listing
- IPO 2021
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 61.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Genetics and genomics, Spinout, Biotech and Pharma, mRNA Medicines, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Jul 2023
- Capital deployed
- $37M
- Preferred round
- Unknown
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $6.4M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2025 | $17M | — | Bloomage Biotech | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$11M | — |
| 2025 | $0 | -100% | −$11M | — |
| 2024 | $1.8M | — | −$31M | -1755.3% |
| 2023 | $0 | — | −$72M | — |
| 2022 | $0 | — | −$93M | — |
| 2021 | $0 | — | −$214M | — |
| 2020 | $0 | — | −$38M | — |
Growth signals
Latest recorded traffic for Sirnaomics is 4.3K monthly website visits, up 65.4% over the last three months. Sirnaomics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EDIRNAGermantown, United States
→
RNAimmuneGaithersburg, United StatesThe company's focus is on developing treatments and cures for complex diseases using mrna technology
$108Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Hong Kong Science & Technology Parks Corporation
Series A2 investors entered at this stage
- MDMaryland Department of Business and Economic Development
- VLValue Measured Investment Limited
Series B and later13 investors entered at this stage
- YFYuexiu Industrial Fund
- QIQianhai Shenghui Investment
- SCSangel Biomedical Venture Capital
- HIHuaKong Equity Investment
- GFGuangzhou YUEXIU Industrial Investment Fund
Walvax Biotechnology
River Head Capital- RFRotating Boulder Fund
Sangel Capital- LCLongmen Capital
Hongtao Capital- ACAlpha Win Capital
Bloomage Biotech
Other known investors1 additional known investor
University of Maryland
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sirnaomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sirnaomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.